| Date | Title | Format |
|---|---|---|
|
April 15, 2026
|
||
|
April 8, 2026
|
||
|
March 18, 2026
|
||
|
March 16, 2026
|
||
|
March 2, 2026
|
||
|
February 25, 2026
|
||
|
February 23, 2026
|
||
|
February 11, 2026
|
||
|
January 9, 2026
|
||
|
January 8, 2026
|
About Amarin

About Amarin
Amarin is an innovative global pharmaceutical company committed to providing cost-effective cardiovascular care to high-risk adult cardiovascular patients.Find out more.
Our Science

Our Science
We use innovative science and research methods to develop new, cost-effective treatments for cardiovascular disease. Discover more about our methodology, trials and CV Health from Amarin.
Investor Relations

Investor Relations
Amarin strives to ensure that our stakeholders have access to appropriate information about our financial growth. Find out more to help you make an independent decision on your investments.
Press Releases
ALL-NP-00022 1/23
©2026 Amarin Pharmaceuticals Ireland Limited.All rights reserved.
AMARIN, VASCEPA, VAZKEPA and REDUCE-IT names and logos are trademarks of Amarin Pharmaceuticals Ireland Limited. | ALL-NP-00014 1/23
Get in touch
Whether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:
Follow us
Follow Amarin on our social channels for the latest company news, product campaigns and industry updates:
This website is intended for global audiences.